Canadian women over 50 years old were studied over a 10-year period to see if those who sustained a fracture (caused by minimal trauma) were receiving the recommended osteoporosis therapy. We found that approximately half of these women were not being treated, indicating a significant care gap in osteoporosis treatment.
Introduction
Prevalent fragility fracture strongly predicts future fracture. Previous studies have indicated that women with fragility fractures are not receiving the indicated treatment. We aimed to describe post fracture care in Canadian women using a large, population-based prospective cohort that began in 1995-1997.
Methods
We followed 5,566 women over 50 years of age from across Canada over a period of 10 years in the Canadian Multicentre Osteoporosis Study. Information on medication use and incident clinical fragility fractures was obtained during a yearly questionnaire or interview and fractures were confirmed by radiographic/medical reports.
Results
Over the 10-year study period, 42-56% of women with yearly incident clinical fragility fractures were not treated with an osteoporosis medication. During year 1 of the study, 22% of the women who had experienced a fragility fracture were on treatment with a bisphosphonate and 26% were on hormone therapy (HT). We were not able to differentiate HT use for menopause symptoms vs osteoporosis. Use of bisphosphonate therapy increased over time; odds ratio (OR) for use at year 10 compared to use at year 1 was 3.65 (95% confidence interval (CI) 1.83-7.26). In contrast, HT use declined, with an OR of 0.07 (95%CI 0.02-0.24) at year 10 compared to year 1 of the study.
Conclusion
In a large population-based cohort study, we found a therapeutic care gap in women with osteoporosis and fragility fractures. Although bisphosphonate therapy usage improved over time, a substantial gap remains.
fragility fractures osteoporosis treatment gap, postmenopausal women fracture care, bisphosphonate therapy underutilization canada, minimal trauma fractures osteoporosis diagnosis, bone density fracture prevention women, osteoporosis medication adherence postmenopausal, hormone therapy versus bisphosphonates osteoporosis, canadian multicentre osteoporosis study, fragility fracture predictors future fracture
Cite this article
Fraser, L. A., Ioannidis, G., Adachi, J. D., Pickard, L., Kaiser, S. M., Prior, J., Brown, J. P., Hanley, D. A., Olszynski, W. P., Anastassiades, T., Jamal, S., Josse, R., Goltzman, D., Papaioannou, A., & CaMos Research Group (2011). Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study. *Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA*, *22*(3), 789-796. https://doi.org/10.1007/s00198-010-1359-2
Fraser LA, Ioannidis G, Adachi JD, Pickard L, Kaiser SM, Prior J, et al. Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study. Osteoporos Int. 2011;22(3):789-796. doi:10.1007/s00198-010-1359-2
Fraser, L. A., et al. "Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study." *Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA*, vol. 22, no. 3, 2011, pp. 789-796.
O'Neill TW et al., 1996Journal of Epidemiology and Community Health
Objective: To determine the risk factors associated with fracture of the distal forearm, and to evaluate the influence of falls on these risks.
Design: This was a case-control study.
Setting: Manchest...
General OB/GYN > Epidemiology > TrendsPerimenopause/Menopause > Bone Health > Fracture Risk
Prevention of early menopausal bone loss may reduce the future burden of osteoporosis. In this modelling exercise, an osteoporosis prevention strategy involving 5-year infusions of zoledronic acid, be...
Perimenopause/Menopause > Bone Health > Fracture Risk
Little is known about the association between health-related quality of life (HRQOL) and osteoporosis in the absence of fracture, and how HRQOL may change over time. This study provides evidence of su...
The HFEA is the independent regulator of fertility treatment in the UK. Part of our role is to collect data from every licensed fertility clinic about the 60,000 treatment cycles they perform each yea...